Trials / Completed
CompletedNCT03507166
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48-ADC | 2 mg/kg IV every 2 weeks |
Timeline
- Start date
- 2017-12-28
- Primary completion
- 2018-10-29
- Completion
- 2018-10-29
- First posted
- 2018-04-24
- Last updated
- 2019-08-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03507166. Inclusion in this directory is not an endorsement.